BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 19157107)

  • 1. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
    Ge JP; Gong J; Ma HQ; Wei W; Shang XJ; Zhang ZY; Xu S; Wang D; Gao JP
    Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
    Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
    Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
    Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
    Sakai H; Igawa T; Onita T; Furukawa M; Hakariya T; Hayashi M; Matsuya F; Shida Y; Nishimura N; Yogi Y; Tsurusaki T; Takehara K; Nomata K; Shiraishi K; Shono T; Aoki D; Kanetake H
    Hinyokika Kiyo; 2011 Jan; 57(1):7-13. PubMed ID: 21304253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
    Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
    Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia].
    Ju XB; Wu HF; Su JT
    Zhonghua Nan Ke Xue; 2002; 8(4):286-8. PubMed ID: 12491697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
    Oh-oka H
    Urol Int; 2009; 82(2):136-42. PubMed ID: 19321997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of naftopidil on nocturia after failure of tamsulosin.
    Oh-oka H
    Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
    Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
    Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia].
    Shang XJ; Liu ZY; Liu ZF; Sun YH; Huang YF
    Zhonghua Nan Ke Xue; 2008 Mar; 14(3):227-30. PubMed ID: 18488335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.